ARGX vs RVMD
argenx SE and Revolution Medicines, Inc., both Healthcare
argenx SE is the larger company at $55B against $35B. Over the past year RVMD returned +517% against +56% for ARGX. Ryufin's sector-relative Smart Score puts RVMD ahead, 10/10 against 7/10.
| Figure | ARGX | RVMD |
|---|---|---|
| Last close | $1047 | $216 |
| Market cap | $55B | $35B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 53.5 | n/a |
| 1-year return | +56% | +517% |
| 5-year return | +239% | +635% |
| Ryufin Smart Scoresector-relative, 1–10 | 7/10 | 10/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
argenx SE
Revenue of $2.5B in H2 2025, net income $877M.
Revolution Medicines, Inc.
Open these two in the interactive comparison to add more names, change the period or read the correlation.